Age and frailty in COVID-19 vaccine development

Melissa K. Andrew; Janet E. McElhaney

doi:10.1016/S0140-6736(20)32481-8

Age and frailty in COVID-19 vaccine development

Melissa K. Andrew, Janet E. McElhaney

Medicine

Research output: Contribution to journal › Comment/debate › peer-review

43 Citations (Scopus)

Original language	English
Pages (from-to)	1942-1944
Number of pages	3
Journal	The Lancet
Volume	396
Issue number	10267
DOIs	https://doi.org/10.1016/S0140-6736(20)32481-8
Publication status	Published - Dec 19 2020

Bibliographical note

Funding Information:
MKA reports grants from the Canadian Frailty Network, Sanofi, Pfizer, and GlaxoSmithKline, personal fees from Pfizer for advisory board membership, and personal fees from Sanofi for advisory board membership and consulting about severe outcomes of influenza in older adults. MKA reports agreement to future payments for serving as a member of the data safety monitoring board for a COVID-19 vaccine trial funded by ImmunoVaccine Technologies. JEM reports personal fees from RestorBio and Sanofi for advisory board membership, GlaxoSmithKline and Merck for data safety monitoring board memberships related to vaccine development outside of COVID-19, and personal fees for serving on the Scientific Advisory Board for an influenza vaccine trial sponsored by Medicago.

ASJC Scopus Subject Areas

General Medicine

PubMed: MeSH publication types

Journal Article
Comment

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0140-6736(20)32481-8

Cite this

@article{9bb5bbddc06d44cc952fa6a2c1b7f324,

title = "Age and frailty in COVID-19 vaccine development",

author = "Andrew, {Melissa K.} and McElhaney, {Janet E.}",

note = "Funding Information: MKA reports grants from the Canadian Frailty Network, Sanofi, Pfizer, and GlaxoSmithKline, personal fees from Pfizer for advisory board membership, and personal fees from Sanofi for advisory board membership and consulting about severe outcomes of influenza in older adults. MKA reports agreement to future payments for serving as a member of the data safety monitoring board for a COVID-19 vaccine trial funded by ImmunoVaccine Technologies. JEM reports personal fees from RestorBio and Sanofi for advisory board membership, GlaxoSmithKline and Merck for data safety monitoring board memberships related to vaccine development outside of COVID-19, and personal fees for serving on the Scientific Advisory Board for an influenza vaccine trial sponsored by Medicago.",

year = "2020",

month = dec,

day = "19",

doi = "10.1016/S0140-6736(20)32481-8",

language = "English",

volume = "396",

pages = "1942--1944",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "10267",

}

TY - JOUR

T1 - Age and frailty in COVID-19 vaccine development

AU - Andrew, Melissa K.

AU - McElhaney, Janet E.

N1 - Funding Information: MKA reports grants from the Canadian Frailty Network, Sanofi, Pfizer, and GlaxoSmithKline, personal fees from Pfizer for advisory board membership, and personal fees from Sanofi for advisory board membership and consulting about severe outcomes of influenza in older adults. MKA reports agreement to future payments for serving as a member of the data safety monitoring board for a COVID-19 vaccine trial funded by ImmunoVaccine Technologies. JEM reports personal fees from RestorBio and Sanofi for advisory board membership, GlaxoSmithKline and Merck for data safety monitoring board memberships related to vaccine development outside of COVID-19, and personal fees for serving on the Scientific Advisory Board for an influenza vaccine trial sponsored by Medicago.

PY - 2020/12/19

Y1 - 2020/12/19

UR - http://www.scopus.com/inward/record.url?scp=85097244714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85097244714&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(20)32481-8

DO - 10.1016/S0140-6736(20)32481-8

M3 - Comment/debate

C2 - 33220853

AN - SCOPUS:85097244714

SN - 0140-6736

VL - 396

SP - 1942

EP - 1944

JO - The Lancet

JF - The Lancet

IS - 10267

ER -

Age and frailty in COVID-19 vaccine development

Bibliographical note

ASJC Scopus Subject Areas

PubMed: MeSH publication types

UN SDGs

Access to Document

Other files and links

Cite this